Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Patients Receiving Antiretroviral Therapy

Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Patients Receiving Antiretroviral Therapy in The Region Of Madrid: A Population-Based, Cross-Sectional Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03123575

Acronym

PODIUM

Enrollment

1000

Registered

2017-04-21

Start date

2017-06-30

Completion date

2017-10-31

Last updated

2017-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Brief summary

This will be a cross-sectional population-based study carried out in the region of Madrid (6,468,322 inhabitants according to current census) to quantify the number of Co-meds in HIV-infected individuals on ART in the region of Madrid, categorized by age and gender, and to compare the number of Co-meds between the ART-treated population and HIV-uninfected population in the region of Madrid, categorized by age and gender.

Detailed description

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Inclusion criteria

* patients who picked-up Co-meds in the study period

Exclusion criteria

* NONE

Design outcomes

Primary

Measure	Time frame	Description
the number of Co-meds in HIV-infected individuals on ART	6 months	number of Co-meds in HIV-infected individuals on ART in the region of Madrid, categorized by age and gender.
number of Co-meds between the ART-treated population and HIV-uninfected	6 months	the number of Co-meds between the ART-treated population and HIV-uninfected population in the region of Madrid, categorized by age and gender.
prevalence of potential CSDIs between ARVs and Co-meds in ART-treated individuals	6 months	prevalence of potential CSDIs between ARVs and Co-meds in ART-treated individuals, with description of the types of harm expected from each different potential CSDIs identified

Contacts

Primary ContactJuan Berenguer, PhD

jbb4@me.com+34620038850

Outcome results